Vera Therapeutics, Inc. VERA
At closeNov 11, 2026, 8:01 AM EST
Pre-market · Nov 11, 8:01 AM ET
- YTD
- -40.70%
- 1 year
- +1.08%
- Market cap
- 2.17B
- Revenue (ttm)
- 10.28M
- EPS (ttm)
- -5.90
- Shares out
- 72.30M
- Forward P/E
- -6.98
- YTD return
- -40.70%
- 1-year return
- +1.08%
- Volume
- 1.85M
- Avg volume
- 2.07M
- Open
- 30.20
- Previous close
- 30.61
- Day's range
- 29.80 – 31.07
- 52-week range
- 26.38 – 56.05
- Beta
- 1.19
- Analysts
- Strong Buy
- Price target
- 71.93 (+139.5%)
- Earnings date
- Feb 25, 2027
5D -1.59 (-5.03%)
Key statistics
- Enterprise value
- 1.91B
- PEG ratio
- 0.00
- Price / sales
- 211.26
- Price / book
- 6.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -244.62M
- Total cash
- 384.04M
- Total debt
- 76.79M
- Return on equity
- -113.46%
- Short % of float
- 21.38%
- 50-day average
- 31.53
- 200-day average
- 36.47
Analyst view
Consensus: strong buy
- Target (low)
- 29.00
- Target (mean)
- 71.93
- Target (high)
- 100.00
- Strong buy1
- Buy11
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -1.42.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -1.51 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.62 | -1.30 | +0.32 | +19.75% |
| Aug 10, 2026 | Jun 30, 2026 | -1.58 | -1.52 | +0.06 | +3.80% |
| May 7, 2026 | Mar 31, 2026 | -1.33 | -1.69 | -0.36 | -27.22% |
| Feb 26, 2026 | Dec 31, 2025 | -1.34 | -1.39 | -0.05 | -3.73% |
| Nov 5, 2025 | Sep 30, 2025 | -1.20 | -1.26 | -0.06 | -5.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Wedbush | main | Neutral | Neutral |
| Nov 6, 2026 | Guggenheim | main | Buy | Buy |
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 12, 2026 | Leerink Partners | init | — | Market Perform |
| Sep 8, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 17, 2026 | Wedbush | reit | Neutral | Neutral |
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- veratx.com
News
Vera Therapeutics, Inc. $VERA Shares Sold by CenterBook Partners LP 
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Vera Therapeutics Q3 Earnings Call Highlights 
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $29 
Guggenheim Maintains Buy on Vera Therapeutics, Lowers Price Target to $66 
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $75 
Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript 
Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates 
Vera Therapeutics Q3 EPS $(1.30) Beats $(1.62) Estimate, Sales $10.277M Beat $3.398M Estimate 
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Your note
Sign in to keep a note on VERA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOMAN NANCY LEE M.D., PH.D. | Officer | Stock Award(Grant) | Aug 2, 2026 | 44,987 |
| BRENNER ROBERT | Officer | Sale | Feb 22, 2026 | 50,947 |
| CARTER JASON S | Officer | Sale | Nov 20, 2025 | 49,136 |
| ENRIGHT PATRICK G. | Director | Purchase | Dec 10, 2025 | 5,400,090 |
| FORDYCE MARSHALL | Chief Executive Officer | Sale | Sep 14, 2026 | 235,244 |
| GRANT SEAN | Chief Financial Officer | Sale | Feb 22, 2026 | 119,181 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.95% | 5,747,760 | 172.61M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 7.92% | 5,723,888 | 171.89M | Jun 29, 2026 |
| State Street Corporation | 5.74% | 4,148,786 | 124.59M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.55% | 4,012,936 | 120.51M | Jun 29, 2026 |
| Deep Track Capital, Lp | 5.53% | 4,000,000 | 120.12M | Jun 29, 2026 |
| Deerfield Management Company, L.P | 5.42% | 3,916,400 | 117.61M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 1,933,728 | 58.07M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.54% | 1,834,397 | 55.09M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 1,654,806 | 49.69M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.40% | 1,014,457 | 30.46M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.21% | 871,547 | 26.17M | Sep 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.08% | 784,306 | 23.55M | Jun 29, 2026 |